Abstract：Objective To compare the clinical effect and safety of Duloxetine and Escitalopram in the treatment of patients with depression,so as to provide reference for the treatment of psychiatric depression.Methods A total of 120 patients with depression admitted to the Department of Psychiatric of Jinzhou Kangning Hospital from February 2018 to February 2020 were selected as the research objects,and the patients were divided into the control group and the observation group by the random number table method,with 60 patients in each group.Patients in the control group were treated with Escitalopram,while patients in the observation group were treated with Duloxetine.The prognostic outcomes of the two groups were compared,including the total effective rate of treatment,the total incidence of adverse reactions and the depression score.Results The total effective rate of patients in the observation group was higher than that in the control group,and the difference was statistically significant (P＜0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group,with statistically significant difference (P＜0.05).There was no significant difference in depression score between the two groups before treatment (P＞0.05).At 1,2,4,and 8 weeks after treatment,the depression scores of patients in the observation group were lower than those in the control group,with statistically significant differences (P＜0.05).Conclusion Both Duloxetine and Escitalopram can be used in the treatment of depression.However,compared with the treatment effect,safety and symptom improvement,Duloxetine has obvious advantages and is the preferred therapeutic drug.
张琎. 度洛西汀与艾司西酞普兰治疗抑郁症患者临床效果及安全性的比较[J]. 中国当代医药, 2021, 28(1): 59-62.
ZHANG Jin. Comparison of clinical effect and safety of Duloxetine and Escitalopram in the treatment of patients with depression. 中国当代医药, 2021, 28(1): 59-62.
Mahajan SS，Tandon VR，Arora，et al.Comparative efficacy and safety of escitalopram ver sus desvenlafaxine in postmenopausal women with depression and anxiety：A randomized，open-label，comparative trial[J].J Midlife Health，2019，10（3）：141-146.
Kang SH，Kim BY，Kwon HI，et al.PLGA Microsphere Addition to 1-Hydroxy-2-napthoic Acid Enhances the Sustained Release of Escitalopram[J].Bull Korean Chem Soc，2019，40（8）：791-795.
京公网安备 11010502046607号